Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: MacroGenics, Inc.

Market Cap 255M 221M 204M 191M 357M 24.41B 364M 2.43B 942M 11.76B 957M 936M 40.9B P/E Ratio 2026 *
-5.98x
P/E Ratio 2027 * -2.62x
Enterprise Value 255M 221M 204M 191M 357M 24.41B 364M 2.43B 942M 11.76B 957M 936M 40.9B EV / Sales 2026 *
1.55x
EV / Sales 2027 * 2.7x
Free-Float
96.57%
Yield 2026 *
-
Yield 2027 * -
1 day+3.62%
1 week-5.65%
Current month-3.61%
1 month+35.93%
3 months+20.06%
6 months+184.40%
Current year+149.07%
1 week 3.81
Extreme 3.81
4.09
1 month 3.28
Extreme 3.28
4.64
Current year 1.58
Extreme 1.58
4.64
1 year 1.18
Extreme 1.185
4.64
3 years 0.99
Extreme 0.9897
21.88
5 years 0.99
Extreme 0.9897
29.16
10 years 0.99
Extreme 0.9897
36.48
Manager TitleAgeSince
Chief Executive Officer 53 13/08/2025
Director of Finance/CFO 59 01/05/2008
Chief Tech/Sci/R&D Officer 61 -
Director TitleAgeSince
Director/Board Member 73 01/09/2001
Director/Board Member 53 13/08/2025
Director/Board Member 62 01/10/2004
Date Insider Type Main position Quantity % Market Cap.
05-19Free

Founder

25,750 0.0405%
05-19Free

Director

25,750 0.0405%
05-19Free

Chairman

25,750 0.0405%
Change 5-day change 1-year change 3-year change Capi.($)
+3.62%-5.65%+134.50%-27.88% 255M
+0.36%+1.59%+53.86%+110.32% 55.58B
+0.03%+0.33%+49.22%+43.94% 43.47B
+3.93%-0.06%-15.10%-18.04% 22.64B
+5.27%-7.82%-1.29%+388.48% 20.96B
+3.81%-5.07%+12.00%-29.52% 15.79B
+0.29%+0.65%+9.27%-39.94% 15.3B
+1.75%+1.92%+29.13%+178.65% 13.45B
+5.27%+5.54%+14.25% - 11.74B
-5.27%-0.43%+87.77%+208.02% 10.96B
Average +1.90%-1.17%+37.36%+90.45% 21.02B
Weighted average by Cap. +1.49%+0.75%+31.65%+97.65%

Financials

2026 *2027 *
Net sales 164M 143M 132M 123M 230M 15.74B 235M 1.57B 607M 7.59B 617M 604M 26.38B 94.26M 81.8M 75.4M 70.65M 132M 9.03B 135M 899M 348M 4.35B 354M 346M 15.13B
Net income -18.31M -15.89M -14.64M -13.72M -25.64M -1.75B -26.17M -175M -67.63M -845M -68.72M -67.24M -2.94B -127M -110M -102M -95.22M -178M -12.16B -182M -1.21B -469M -5.86B -477M -467M -20.39B
Net Debt - -
Logo MacroGenics, Inc.
MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its other product candidates are MGD024, retifanlimab, enoblituzumab, and vobramitamab duocarmazine. MGD024 is an investigational, next-generation, bispecific CD123 CD3 DART molecule designed to engage CD3 expressed on immune effector cells, such as T cells.
Employees
293
Date Price Change Volume
11/06/26 4.010 $ +3.62% 712,672
10/06/26 3.870 $ -1.02% 501,196
09/06/26 3.910 $ +0.77% 532,407
08/06/26 3.880 $ -0.77% 641,177
05/06/26 3.910 $ -8.00% 560,054
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
4.010USD
Average target price
6.750USD
Spread / Average Target
+68.33%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MGNX Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!